Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Fair Value Measurements (Details Textual)

v3.8.0.1
Note 4 - Fair Value Measurements (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 15 Months Ended
Mar. 31, 2018
Sep. 30, 2017
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Jun. 30, 2017
Aug. 01, 2016
Mar. 14, 2016
Nov. 03, 2014
Payment for Contingent Consideration Liability     $ 85,000            
Payment for Contingent Consideration Liability, Financing Activities     58,800 $ 14,203 $ 58,800        
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability     (26,200) $ (9,117) (26,200)        
Advanced Cell Diagnostics (ACD) [Member]                  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 75,000   75,000   75,000 $ 50,000      
Business Combination, Liabilities Arising from Contingencies, Amount Recognized             $ 37,000    
Payment for Contingent Consideration Liability 50,000                
Zephyrus [Member]                  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 7,000   7,000   7,000 3,500      
Business Combination, Liabilities Arising from Contingencies, Amount Recognized               $ 6,500  
CyVek, Inc. [Member]                  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 35,000   35,000   35,000 $ 35,000      
Business Combination, Liabilities Arising from Contingencies, Amount Recognized                 $ 35,000
Payment for Contingent Consideration Liability   $ 35,000              
Advance Cell Diagnostics (ACD), Zephyrus, and CyVek Inc.[Member]                  
Business Combination, Liabilities Arising from Contingencies, Amount Recognized $ 78,500   $ 78,500   $ 78,500